Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories has announced the successful closure of the USFDA inspection at their API manufacturing facility in Srikakulam, Andhra Pradesh, with a classification of Voluntary Action Indicated (VAI). This update indicates the company’s commitment to maintaining regulatory compliance and could impact investor confidence positively.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.